Abstract
To elucidate whether density of cells could contribute to the extent of microglial activation, we performed in vitro assays using three different densities of N13 microglia stimulated with LPS. Our results showed that induction of pro-inflammatory factors as TNF-α and iNOS was directly related to cell density, meanwhile the induction of the anti-inflammatory IL-10 was inversely related to cell density. Accordingly, in vivo assays showed that after LPS-injection, iNOS expression was more intense in substantia nigra, a brain area showing specific susceptibility to neurodegeneration after microglia activation, whereas IL-10 expression was more sustained in striatum, an area resistant to damage. These results support that microglia density is pivotal to control the balance between pro- and anti-inflammatory factors release.
Copyright © 2011 Elsevier B.V. All rights reserved.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Analysis of Variance
-
Animals
-
Anti-Inflammatory Agents / therapeutic use
-
Cell Count
-
Cell Line, Transformed
-
Cytokines / genetics
-
Cytokines / metabolism*
-
Disease Models, Animal
-
Encephalitis / chemically induced*
-
Encephalitis / drug therapy
-
Encephalitis / pathology*
-
Enzyme-Linked Immunosorbent Assay / methods
-
Gene Expression Regulation
-
Imidazoles / therapeutic use
-
Interleukin-10 / genetics
-
Interleukin-10 / metabolism
-
Isothiuronium / analogs & derivatives
-
Isothiuronium / therapeutic use
-
Lipopolysaccharides / toxicity*
-
Male
-
Mice
-
Microglia / drug effects*
-
Microglia / pathology
-
Nitric Oxide Synthase Type II / genetics
-
Nitric Oxide Synthase Type II / metabolism*
-
Pyridines / therapeutic use
-
RNA, Messenger / metabolism
-
Rats
-
Tumor Necrosis Factor-alpha / genetics
-
Tumor Necrosis Factor-alpha / metabolism
Substances
-
Anti-Inflammatory Agents
-
Cytokines
-
Imidazoles
-
Lipopolysaccharides
-
Pyridines
-
RNA, Messenger
-
Tumor Necrosis Factor-alpha
-
Interleukin-10
-
Isothiuronium
-
Nitric Oxide Synthase Type II
-
S-methylisothiopseudouronium
-
SB 203580